Abstract 98P
Background
Capecitabine and oxaliplatin combination regimen (CAPOX) is the standard chemotherapeutic care for the treatment of colorectal cancer (CRC). CAPOX treatment is found to be equivalent to FOLFOX and FOLFRI in efficacy and preferred over them due to its easy management and convenience in administration. However, CAPOX treatment was associated with several dose-limiting toxicities and high inter-individual variation in toxicity profile. These toxicities may limit treatment effectiveness as they impose treatment interruption or even discontinuation. Therefore, there is a critical need for identifying the predictive biomarkers for CAPOX related toxicities.
Methods
Patients and methods: In an intent treat analysis, 145 CRC patients were recruited. Patients received a standard treatment schedule of oxaliplatin 130 mg/m2 infusion over 2 hours on day 1 and oral capecitabine 1000mg/m2 in divided doses twice daily for the next 14 days of a 21-day cycle. 5 ml of the venous blood was collected from each patient and genomic DNA was extracted by the phenol-chloroform method. The genotyping analysis of the selected SNP’s was carried out by real-time PCR using TaqMan SNP genotyping assays from applied biosystems.
Results
The major dose-limiting toxicities observed with CAPOX treatment were thrombocytopenia, HFS and PN. DPYD*9 carries were found to be at higher risk for HFS, diarrhoea and thrombocytopenia when compared to patients with wild allele. No significant association was found between DPYD*6, GSTP1 ile105val polymorphisms and CAPOX related toxicities except for thrombocytopenia.
Conclusions
A significant association was observed between DPYD*9A A>G polymorphism and CAPOX induced dose-limiting toxicities like HFS, diarrhoea and thrombocytopenia strengthening its role as a predictive biomarker.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ashok Varma.
Funding
Jawaharlal Institute of Post-Graduate Medical Education and Research (JIPMER).
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract